Galectins-1,-3 and-9 Are Present in Breast Milk and Have a Role in Early Life Development

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Rio-Aige, Karla
  • Girbal, Marina
  • Gonzalez, Sonia
  • Martinez-Costa, Cecilia
  • Castell, Margarida
  • Carmen Collado, Maria
  • Perez-Cano, Francisco J.
  • Rodriguez-Lagunas, Maria J.

Grups d'Investigació

Abstract

Galectins (Gal) are a family of conserved soluble proteins with high affinity for beta-galactoside structures. They have been recognized as important proteins for successful pregnancy. However, little is known about their presence in breast milk and their role in early infancy. Gal-1, -3 and -9 concentrations were evaluated by Multiplex immunoassays in mother-infant pairs from the MAMI cohort in maternal plasma (MP) (n = 15) and umbilical cord plasma (UCP) (n = 15) at birth and in breast milk samples (n = 23) at days 7 and 15 postpartum. Data regarding mother and infant characteristics were collected. Gal-9 was present in a lower concentration range than Gal-1 and Gal-3 in plasma, specifically in UCP. A major finding in the current study is that Gal-1, -3 and -9 were detected for the first time in all the transitional breast milk samples and no differences were found when comparing the two breastfeeding time points. Finally, Gal levels were associated with some maternal and infant characteristics, such as gestational age, pregnancy weight gain, maternal diet, the gender, infant growth and infant infections. In conclusion, Gal levels seem to be involved in certain developmental aspects of early life.

Dades de la publicació

ISSN/ISSNe:
2072-6643, 2072-6643

Nutrients  MDPI

Tipus:
Article
Pàgines:
-
PubMed:
36297023
Factor d'Impacte:
1,287 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 1

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • galectin; breast milk; umbilical cord plasma; maternal plasma

Projectes associats

RED DE SALUD MATERNO-INFANTIL Y DEL DESARROLLO.

Investigador Principal: MÁXIMO VENTO TORRES

RD16/0022/0001 . INSTITUTO DE SALUD CARLOS III . 2017

Variaciones epigenómicas asociadas al inicio y curso de los trastornos del neurodesarrollo en prematuros: estudio de cohorte a 6 años.

Investigador Principal: ANA CRISTINA GARCÍA BLANCO

PI18/01352 . INSTITUTO DE SALUD CARLOS III . 2019

EVOLUCIÓN DE LOS MARCADORES INFLAMATORIOS EN UNA COHORTE DE RECIÉN NACIDOS PRETÉRMINO DE MUY BAJO PESO Y SU RELACIÓN CON LA APARICIÓN DE DISPLASIA BRONCOPULMONAR.

Investigador Principal: ANA GIMENO NAVARRO

PI-1774

TARGETED OXYGENATION IN THE RESPIRATORY CARE OF PREMATURE INFANTS AT DELIVERY: EFFECTS ON OUTCOME (TORPIDO 30/60)./ OXIGENACIÓN DIRIGIDA EN LA ATENCIÓN RESPIRATORIA DE BEBÉS PREMATUROS EN EL PARTO: EFECTOS SOBRE EL RESULTADO (TORPIDO 30/60).

Investigador Principal: MÁXIMO VENTO TORRES

CTC022ACTRN12618000879268 . 2021

DETECCIÓN PRECOZ DE LA ENTEROCOLITIS NECROTIZANTE A PARTIR DE UN MODELO PREDICTIVO BASADO EN TÉCNICAS ÓMICAS.

Investigador Principal: ANNA PARRA LLORCA

2021-727-1_CRC_PARRA . ORDESA . 2021

Estudio de fase 1b, aleatorizado, ciego y de búsqueda de dosis para evaluar el perfil de seguridad y tolerabilidad de la administración de AT-100 (rhSP-D: proteína surfactante D humana recombinante) en recién nacidos prematuros con alto riesgo de desarrollo de displasia broncopulmonar (DBP).

Investigador Principal: MARTA AGUAR CARRASCOSA

AT-100/001 . 2022

Compartir la publicació